Pathobiologic characteristics of hereditary breast cancer

被引:67
作者
Lynch, BJ
Holden, JA
Buys, SS
Neuhausen, SL
Gaffney, DK
机构
[1] Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA
[2] Univ Utah, Dept Internal Med, Salt Lake City, UT 84132 USA
[3] Univ Utah, Dept Med Informat, Salt Lake City, UT 84132 USA
[4] Univ Utah, Dept Radiat Oncol, Salt Lake City, UT 84132 USA
关键词
hereditary breast cancer; BRCA1; BRCA2; immunohistochemical staining; DNA topo II-alpha;
D O I
10.1016/S0046-8177(98)90427-0
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Patients with hereditary breast cancer (HBC) present at a young age with breast cancers that show adverse pathological characteristics such as high nuclear grade, negative hormone receptor status, and high proliferation indices. Surprisingly, the clinical course has been reported to be comparable or improved compared with patients with nonhereditary breast cancer (non-HBC). To determine whether there are any molecular markers that might help explain this paradox between pathologically aggressive neoplasms in patients with HBC and the lack of extreme clinically aggressive disease, we studied several molecular parameters in a group of 34 breast cancer patients with mutations in either the BRCA1 or BRCA2 tumor suppressor genes and compared them with a group of 20 breast cancer patients with non-HBC. In general, patients with HBC had tumors that were of higher nuclear grade, contained a higher population of proliferating cells, showed increased expression of DNA topoisomerase II-alpha (topo II-alpha), lacked hormone receptors, and were more likely to show immunopositivity for the p53 tumor suppressor gene, Additionally, tumors from patients with HBC showed a decreased angiogenesis compared with controls. The decreased angiogenesis and the elevated expression of tops II-alpha (an anticancer drug target) may, in part, explain the lack of correlation between clinical course and histological characteristics in patients with HBC. Copyright (C) 1998 by W.B. Saunders Company.
引用
收藏
页码:1140 / 1144
页数:5
相关论文
共 29 条
[1]  
ALBANO WA, 1982, CANCER, V50, P360, DOI 10.1002/1097-0142(19820715)50:2<360::AID-CNCR2820500233>3.0.CO
[2]  
2-4
[3]   HISTOPROGNOSTIC GRADE IN TUMORS FROM FAMILIES WITH HEREDITARY PREDISPOSITION TO BREAST-CANCER [J].
BIGNON, YJ ;
FONCK, Y ;
CHASSAGNE, MC .
LANCET, 1995, 346 (8969) :258-258
[4]  
Brambilla E, 1996, AM J PATHOL, V149, P1941
[5]  
Charpin C, 1996, AM J CLIN PATHOL, V106, P640
[6]   THE IMPORTANCE OF HISTOLOGIC GRADE IN LONG-TERM PROGNOSIS OF BREAST-CANCER - A STUDY OF 1,010 PATIENTS, UNIFORMLY TREATED AT THE INSTITUT-GUSTAVE-ROUSSY [J].
CONTESSO, G ;
MOURIESSE, H ;
FRIEDMAN, S ;
GENIN, J ;
SARRAZIN, D ;
ROUESSE, J .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) :1378-1386
[7]   p53 mutations in BRCA1-associated familial breast cancer [J].
Crook, T ;
Crossland, S ;
Crompton, MR ;
Osin, P ;
Gusterson, BA .
LANCET, 1997, 350 (9078) :638-639
[8]  
Dawson-Saunders B., 1994, Basic and clinical biostatistics, V2
[9]  
Eisinger F, 1996, CANCER RES, V56, P471
[10]   Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer [J].
FitzGerald, MG ;
MacDonald, DJ ;
Krainer, M ;
Hoover, I ;
ONeil, E ;
Unsal, H ;
SilvaArrieto, S ;
Finkelstein, DM ;
BeerRomero, P ;
Englert, C ;
Sgroi, DC ;
Smith, BL ;
Younger, JW ;
Garber, JE ;
Duda, RB ;
Mayzel, KA ;
Isselbacher, KJ ;
Friend, SH ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (03) :143-149